Atherosclerosis in type 2 diabetes: a role for fibrate therapy?
Atherosclerosis in type 2 diabetes: a role for fibrate therapy?
复制标题
DOI：
10.3132/dvdr.2007.067
复制
发表时间：
2007-12-01
影响因子：
2.4
通讯作者：
Steiner, George
中科院分区：
文献类型：
--
作者：
Steiner, George
与2型糖尿病相关的血管并发症导致显著的发病率和死亡率。动脉粥样硬化的发展要比没有糖尿病的受试者早得多，进展也更快。与2型糖尿病相关的心血管危险因素的聚集是加速动脉粥样硬化疾病的主要原因。虽然他汀类药物仍然是主要的调脂治疗，但贝特类药物的药理学特征表明，它有可能作为降低2型糖尿病动脉粥样硬化血管并发症风险的替代或额外治疗。
Vascular complications associated with type 2 diabetes confer significant morbidity and mortality. Atherosclerosis develops much earlier and progresses more rapidly than in subjects without diabetes. The clustering of cardiovascular risk factors associated with type 2 diabetes is mainly responsible for accelerated atherosclerotic disease. While statins remain the primary lipid-modifying therapy, the pharmacological profile of the fibrates suggests potential as an alternative or additional treatment for reducing the risk of atherosclerotic vascular complications in type 2 diabetes.